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Abstract
Staphylococcus pseudintermedius is a major cause of skin and soft tissue
infections in companion animals and has zoonotic potential. Additionally,
methicillin-resistant S. pseudintermedius (MRSP) has emerged with resistance to
virtually all classes of antimicrobials. Thus, novel treatment options with new modes
of action are required. Here, we investigated the antimicrobial activity of six
synthetic short peptides against clinical isolates of methicillin-susceptible and
MRSP isolated from infected dogs. All six peptides demonstrated potent anti-
staphylococcal activity regardless of existing resistance phenotype. The most
effective peptides were RRIKA (with modified C terminus to increase amphipathicity
and hydrophobicity) and WR-12 (a-helical peptide consisting exclusively of arginine
and tryptophan) with minimum inhibitory concentration50 (MIC50) of 1 mM and MIC90
of 2 mM. RR (short anti-inflammatory peptide) and IK8 ‘‘D isoform’’ demonstrated
good antimicrobial activity with MIC50 of 4 mM and MIC90 of 8 mM. Penetratin and
(KFF)3K (two cell penetrating peptides) were the least effective with MIC50 of 8 mM
and MIC90 of 16 mM. Killing kinetics revealed a major advantage of peptides over
conventional antibiotics, demonstrating potent bactericidal activity within minutes.
Studies with propidium iodide and transmission electron microscopy revealed that
peptides damaged the bacterial membrane leading to leakage of cytoplasmic
contents and consequently, cell death. A potent synergistic increase in the
antibacterial effect of the cell penetrating peptide (KFF)3K was noticed when
combined with other peptides and with antibiotics. In addition, all peptides displayed
synergistic interactions when combined together. Furthermore, peptides
demonstrated good therapeutic indices with minimal toxicity toward mammalian
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cells. Resistance to peptides did not evolve after 10 passages of S.
pseudintermedius at sub-inhibitory concentration. However, the MICs of amikacin
and ciprofloxacin increased 32 and 8 fold, respectively; under similar conditions.
Taken together, these results support designing of peptide-based therapeutics for
combating MRSP infections, particularly for topical application.
Introduction
Methicillin-susceptible Staphylococcus pseudintermedius (MSSP) and methicillin-
resistant S. pseudintermedius (MRSP) are a leading cause of skin and ear infections
and post-operative wound infections in dogs and cats [1, 2]. S. pseudintermedius
isolates can also cause infections in humans as apparent zoonotic transfer from
dogs has been reported [2–5]. Similar to methicillin-resistant Staphylococcus
aureus (MRSA), MRSP is a nosocomial pathogen that can colonize personnel in
veterinary hospitals [1, 6]. Recent studies reported that MRSP from Europe and
North America emerged resistance to virtually all classes of antimicrobial agents
used in veterinary medicine [7]. Such dissemination of multidrug resistant
staphylococci among dogs raises concern due to the few therapeutic options
available for treatment [8]. Therefore, there is an urgent need for novel
antimicrobial compounds with new mechanisms of action.
Antimicrobial peptides (AMPs) serve as an alternative novel therapeutic
approach against microbial infections. AMPs constitute the first line of defense
against invading pathogens in most multicellular organisms. They have been
discovered from a broad range of organisms, from microorganisms to plants and
from insects to mammals [9]. AMPs are generally between 12 and 50 amino acids
in length with a cationic charge and contains up to 50% hydrophobic amino
acids. They have the ability to form an amphipathic secondary structure that
allows the peptides to partition into the bacterial membrane lipid bilayer [10].
The mechanism of action of AMPs involves binding to the negatively charged
anionic phospholipids on lipopolysaccharide (LPS) of Gram-negative bacteria or
to the teichoic acids of Gram-positive bacteria. Once peptides aggregate in
sufficient concentration, they destabilize the lipid head groups and produce pores
in the cell membrane leading to leakage of cytoplasmic contents and bacterial cell
death [9, 11]. However, membrane disruption is not the only proven mechanism
of bacterial killing by AMPs. Instead, peptides can traverse bacterial membranes
and induce killing through inhibition of specific macromolecular synthesis
pathways [11].
Several studies have reported the potency of AMPs in combating S. aureus
infections [12, 13]; however, to our knowledge, there are limited data about their
activity and potential use against S. pseudintermedius [14, 15]. In the present
study, we investigated the antimicrobial activity of six synthetic short peptides
against clinical isolates of MSSP and MRSP from infected dogs. Moreover, we
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performed a series of experiments to explore their antibacterial mechanism of
action. Finally we examined their toxicity toward mammalian cells and assessed
the ability of S. pseudintermedius to develop resistance to peptides.
Materials and Methods
Peptides, antibiotics and reagents
Peptides (RRIKA, RR, WR-12, IK8 ‘‘D isoform’’, (KFF)3K and penetratin) were
synthesized by GenScript (Piscataway, NJ) using solid-phase 9-fluorenylmethoxy
carbonyl (Fmoc) chemistry and purified to a purity of 98% using reverse-phase
high-performance liquid chromatography (HPLC). Peptide mass was confirmed
by mass spectrometry (Table 1). Nisin (Sigma, N5764), melittin from honey bee
venom (Sigma, M2272), ampicillin sodium salt (IBI Scientific), ciprofloxacin
(Sigma), amikacin hydrate (Sigma) and propidium iodide (Molecular Probes, Life
Technologies) were all purchased from commercial vendors. Mueller-Hinton
broth (MHB) and Mueller-Hinton agar (MHA) were purchased from Sigma-
Aldrich, while trypticase soy broth (TSB) and trypticase soy agar (TSA) were
purchased from Becton-Dickinson, Cockeysville, Md.
Bacterial isolates
Forty isolates of S. pseudintermedius (30 MSSP and 10 MRSP) identified at the
Indiana Animal Disease Diagnostic laboratory from specimens collected from
dogs admitted to the small animal teaching hospital at Purdue University were
included in the study (Tables 2 and 3). Clinical specimens were inoculated onto
5% sheep blood agar and incubated at 35 C̊ for 18–24 hours. White, beta-
hemolytic colonies with morphology suggestive of Staphylococcus sp. were used to
inoculate a coagulase tube test and were identified to the species level using the
Vitek 2 (BioMérieux). Vitek identification of S. pseudintermedius was confirmed
by a positive coagulase test. Antimicrobial susceptibility was determined by broth
microdilution using the SensiTitre (Trek). Isolates demonstrating resistance to
oxacillin, a surrogate for methicillin, with a MIC greater than or equal to 0.5 mg/
mL were screened for mecA by PCR as previously described [16]. A mecA positive
result was assigned to samples with a visible 310 bp band on a 1.5% agarose gel.
Antibacterial assays
The broth microdilution technique was used to determine the minimum
inhibitory concentrations (MIC) of peptides and antibiotics in MHB in
accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines
[17]. Peptides were dissolved in sterile distilled water containing 0.02% acetic
acid. MIC assays were carried out with an initial bacterial inoculum of 56105
colony forming unit (CFU/ml). Peptides and antibiotics were added to
Polystyrene 96 well plates (CytoOne, CC7672-7596) at desired concentrations and
plates were incubated for 24 hr at 37 C̊. MIC was defined as the lowest
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concentration of peptide which inhibited the visible growth of bacteria. MIC was
done in triplicates and the highest value was reported.
Time kill assay
One strain of MRSP (SP3) was grown overnight in MHB, then diluted in fresh
MHB and incubated for 2 hr until logarithmic growth phase was achieved. Then
bacteria were centrifuged and washed twice with phosphate buffered saline (PBS)
and adjusted to ,56105 CFU/ml in MHB. Peptides and antibiotic (amikacin) at
5X MIC were added in triplicates to adjusted bacteria, and incubated aerobically
at 37 C̊. Aliquots at specified time points were taken, serially diluted in PBS and
plated in triplicate on MHA. CFUs were counted after incubation of plates for
24 hr at 37 C̊.
Growth Kinetics
The turbidity of bacterial culture after exposure to peptides was measured as
described previously [13]. Briefly, logarithmic growth of SP 3 was diluted in MHB
to reach OD600<0.25. One mL of diluted bacteria was added to a plastic cuvette
(light path 1 cm). Peptides and antibiotics were added to cuvettes at a
concentration equivalent to 5 X MIC as determined in antibacterial assays above.
Cuvettes were incubated aerobically at 37 C̊. At specific time points, OD was
measured at 600 nm wavelength by spectrophotometer. Cuvettes containing
MHB without bacteria and with the same concentrations of peptide or antibiotic
served as blanks. Nisin at 5 X MIC and untreated bacteria were used as positive
and negative controls, respectively. The assay was repeated twice and the average
was reported.
Bacterial membrane permeability
Bacterial membrane damage was assessed by fluorescence change of propidium
iodide dye as described previously [18]. Briefly, SP3 was grown in MHB to
logarithmic phase of growth then diluted to OD600<0.25. Propidium iodide was
Table 1. Amino acid sequence and physicochemical properties of peptides used in this study.
Peptide designation Amino acid sequencea Length Molecular weight Charge
Hydrophobic amino
acids
RR WLRRIKAWLRR 11 1553.9 +5 54%
RRIKA WLRRIKAWLRRIKA 14 1866.3 +6 57%
WR-12 RWWRWWRRWWRR 12 2072.4 +6 50%
IK8 ‘‘D isoform’’1 irikirik 8 1040.28 +4 50%
(KFF)3K KFFKFFKFFK 10 1413.7 +4 60%
penetratin RQIKIWFQNRRMKWKK 16 2246.7 +7 37%
1D-amino acid substitution.
aSmall underlined residues represent D-amino acids.
doi:10.1371/journal.pone.0116259.t001
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Table 2. Minimum inhibitory concentration (MIC) of peptides against methicillin sensitive Staphylococcus pseudintermedius (MSSP) strains.




SP1 urine 1 4 2 4 4 8 PEN, AMP
SP2 urine 2 8 2 8 16 16 PEN, AMP, CLIN, ENRO, ERYTH, GEN,MARBO, TMP-
SMX
SP4 urine 2 4 4 8 16 16 PEN, AMP, TMP-SMX
SP6 ear 2 4 1 4 16 8 -
SP7 ear 1 4 2 4 8 8 AMK, PEN,AMP,CLIN,ENR,ERM,GEN,MARB, TMP-
SMX
SP10 urine 1 4 1 4 8 8 PEN,AMP,CLIN, ERM, TMP-SMX
SP11 hair 1 4 1 4 8 8 PEN, AMP,CHL,CLIN,
SP12 urine 0.5 0.5 0.5 0.5 8 4 PEN,AMP,AMK,ENR,GEN,MARB, TMP-SMX
SP13 skin abscess 1 4 0.5 4 8 8 PEN,AMP
SP14 ear 2 4 4 4 8 8 PEN,CHL,CLIN,ERM,




2 8 1 8 8 8 -
SP17 skin abscess 1 8 2 8 32 8 PEN, AMP, AMK,CLIN,ENR,ERM,GEN,MARB, TMP-
SMX




1 4 1 4 8 8 PEN,AMP,CEF
SP20 urine 1 4 1 8 16 16 PEN,AMP,DOX
SP21 urine 1 4 1 4 8 8 -
SP22 bladder swab 1 4 1 8 16 8 -
SP23 wound 1 4 1 4 8 8 PEN,AMP,
SP24 abscess 1 4 2 8 16 8 PEN








1 4 1 4 8 8 PEN,AMK,CLIN,ERM,GEN, TMP-SMX
SP31 abscess 1 4 1 4 4 8 -
SP32 abscess 1 4 0.5 4 4 8 PEN,AMP,AMK,ERM,CLIN,GEN, TMP-SMX
SP33 conjunctiva 1 4 0.5 4 8 8 BAC,CIP,ERM,MOX,NEO,OXY, TMP-SMX
SP34 urine 2 4 2 8 8 8 -
SP35 urine 2 4 1 4 8 8 -
SP36 swab at bone
plating
2 8 1 8 8 8 PEN,AMP,CLIN,ENR,ERM,MARB, TMP-SMX
SP37 urine 0.5 4 2 4 8 8 PEN and AMP
MIC50 1 4 1 4 8 8
MIC90 2 8 2 8 16 16
Abbreviation: PEN: penicillin, AMP, ampicillin, AMK: amikacin, CEF: cefpodxime, CLIN: clindamycin, GEN:gentamycin, CHL: chloramphenicol, ENR:
enrofloxacin, MARB: marbofloxacin, ERM: erythromycin, BAC: bacitracin, NEO: neomycin, TOB: tobramycin, CIP: ciprofloxacin, OXY: Oxytetracyclin, TMP-
SMX: trimethoprime sulphamethoxazole.
doi:10.1371/journal.pone.0116259.t002
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mixed with bacteria to a final concentration of 10 mM. Aliquots of 200 mL were
then loaded into black wall 96 microplates and drugs were added at 5 X and 10 X
MIC in triplicate. Fluorescence was monitored for 30 minutes at excitation and
emission wavelengths of 585 and 620 nm, respectively, using a fluorescence plate
reader (FLx800 model BioTek Instruments, Inc. Winooski, Vermont). The
percentage of membrane permeabilization was calculated as the percent of
fluorescent intensity of peptide-treated samples with respect to fluorescence
intensity of propidium iodide-loaded, peptide untreated samples.
Transmission electron microscopy
SP3 was grown to OD600<0.2. Bacterial cells were harvested by centrifugation,
resuspended in PBS, and treated with peptides at 10 X MIC for 30 minutes.
RRIKA and penetratin were also tested at lower concentration 1 X MIC to study
the concentration-dependent effect of peptides. After treatment with peptides, the
bacterial pellets were fixed with 2.5% buffered glutaraldehyde for 1 hour. After
fixation, cells were treated with 1% buffered osmium tetroxide for 1 hour, stained
en bloc with 1% uranyl acetate, dehydrated in a graded series of ethanol, and
embedded in white resin. The buffer used was 0.1M sodium cacodylate, pH 7.4.
Ultrathin sections were prepared on Formvar-coated grids and stained with 1%
uranyl acetate and lead citrate. Microscopy was performed with a Philips CM-100
microscope under standard operating conditions.
Synergism studies
The synergistic effect between peptides and antimicrobial agents was determined
by the combination assay as described previously [19]. Peptide MICs against SP3
were determined in triplicate. Two-fold serial dilutions of antimicrobials
(antibiotic and peptides) were tested in the presence of a fixed concentration of
peptide of concern (equal to J6peptide MIC, which did not inhibit the growth
of bacteria alone). The fractional inhibitory concentration (FIC) index was
calculated as follows: FIC of drug A5MIC of drug A in combination/MIC of drug
A alone, FIC of drug B5MIC of drug B in combination/MIC of drug B alone, and
FIC index5FIC of drug A+FIC of drug B. An FIC index of #0.5 is considered to
demonstrate synergy. Additive was defined as an FIC index of 1. Antagonism was
defined as an FIC index of .4.
Cytotoxicity analysis
Peptides were assayed at different concentrations against macrophage-like cell line
(J774A.1) and human keratinocyte (HaCat) to determine the potential toxic effect
in vitro. Briefly, J774A.1 and HaCat cells were seeded at a density of 1.56104 per
well in a tissue culture 96-well plate (CytoOne, CC7682-7596) in DMEM media
supplemented with 10% fetal bovine serum (FBS), and incubated at 37 C̊ in a 5%
CO2 atmosphere for 24 hours. The cells were treated with peptides at
concentrations range from 8 to 256 mM for 24 hours. Untreated cells were used as
Targeting Multi-Drug Resistant Staphylococcus pseudintermedius
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a negative control. Melittin 5 mM and DMSO 10% were used as a positive control
for J774A.1 and HaCat cells, respectively. After incubation, the cells were washed
three times with PBS and the media in each well were replaced with 100 mL of
DMEM media and 20 mL of assay reagent, MTS 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega,
Madison, WI, USA). The cells were incubated further for 4 h at 37 C̊. Corrected
absorbance readings (actual absorbance readings for each treatment subtracted
from background absorbance) were taken using a kinetic ELISA microplate reader
(Molecular Devices, Sunnyvale, CA, USA). Cell viability was expressed as
percentage of absorbance in comparison to negative control, untreated cells.
Therapeutic index of the peptides, was calculated as the ratio of mammalian IC50
(the concentration of peptide which inhibit 50% of mammalian cells) to
geometric mean of the MIC of peptides against S. pseudintermedius [20]
Multi-step resistance selection
To assess the ability of S. pseudintermedius to develop resistance to the peptides
and antibiotics we used amikacin and ciprofloxacin-susceptible strain (SP6) in a
multi-step resistance selection experiment (Table 2). SP6 strain was exposed for
ten passages over a period of ten days to various concentrations of the peptides
(RRIKA and IK8 ‘‘D isoform’’) and antibiotics (amikacin and ciprofloxacin). For
each subsequent passage, the inoculum for the MIC determination was adjusted
to a final density of approximately 56105 CFU/mL using the bacterial cells
growing at sub-inhibitory concentration (1/2 X MIC). Bacteria were incubated for
16 hr and the MIC value was recorded for each passage. Results were expressed as
the ratio of MIC value after each passage compared to the initial MIC value.
Statistical analyses
Cytotoxicity data were subjected to statistical analysis using GraphPad Prism 6.0
(GraphPad Software, La Jolla, CA). Cytotoxicity data were analyzed using one-




The amino acid sequences and characteristics of the synthetic peptides used in this
study are shown in Table 1. All synthetic peptides demonstrated potent inhibitory
activity. As shown in Table 2, the most effective peptides were RRIKA and WR-12
with MIC50 and MIC90 (the MICs at which 50% and 90% of the isolates were
inhibited, respectively) were found to be 1 mM and 2 mM, respectively. RR and
IK8 ‘‘D isoform’’ demonstrated good antimicrobial activity with MIC50 of 4 mM
and MIC90 of 8 mM. Penetratin and (KFF)3K were the least effective with MIC50 of
8 mM and MIC90 of 16 mM.
Targeting Multi-Drug Resistant Staphylococcus pseudintermedius
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The MICs for MRSP were not significantly different from those for the
nonresistant strains. Interestingly, some peptides (such as Penetratin and
(KFF)3K) demonstrated lower MICs values for methicillin-resistant (MIC50 and
MIC90 equal to 4 and 8 mM, respectively) compared to methicillin sensitive strains
(Table 3).
Time kill assay
To determine the killing kinetics of peptides, we exposed a MRSP strain (SP3) to 5
X MIC of peptides and control antibiotic (amikacin). As depicted in Fig. 1, all
peptides demonstrated rapid bactericidal activity. RRIKA, RR and (KFF)3K were
the most rapid in killing as viable MRSP were not detectable after 10 minutes.
Penetratin, IK8 ‘‘D isoform’’ and WR-12 achieved more than 5 log10 reduction
within 25, 45 and 60 minutes respectively. In contrast, amikacin achieved less
than one log10 reduction within 3 hours and demonstrated bactericidal activity
only after 12 hr (data not shown).
Growth kinetics
As a primary objective to understand the mechanism of action of peptides against
S. pseudintermedius, we monitored the turbidity of SP3 culture exposed to 5 X
MIC of peptides over time by a spectrophotometer. As shown in Fig. 2, all
peptides reduced the optical density of S. pseudintermedius suspensions, and the
degree of reduction over time varied among peptides. Results for RRIKA, RR and
(KFF)3K were similar in rate and percentage to the rapidly acting membrane-
damaging peptide, nisin [21]. These peptides produced greater than 50% and 95%
reductions in turbidity after 60 and 120 minutes, respectively. IK8 ‘‘D isoform’’
and WR-12 achieved a similar percentage of turbidity reduction as nisin albeit at a
slower rate (after 3 and 7 hours). However, the culture turbidity of SP exposed to
Fig. 1. Bacterial killing kinetics of peptides (RRIKA, RR, WR-12, (KFF)3K, IK8 ‘‘D isoform’’ and
penetratin) and antibiotics amikacin at 5X MIC against SP 3 in MHB (Mueller Hinton broth). Samples
treated with peptide diluent (sterile water plus 0.2% acetic acid) were used as a control. The killing curves
were identical (overlapping in the figure) for RRIKA, RR and (KFF)3K. The results are given as means ¡ SD
(n53; data without error bars indicate that the SD is too small to be seen).
doi:10.1371/journal.pone.0116259.g001
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penetratin remained constant for 2 hours, and turbidity was reduced by less than
50% after 7 hours. In contrast, a DNA synthesis inhibitor, ciprofloxacin, and a
protein synthesis inhibitor, amikacin, did not reduce the culture turbidity within
the same time frame, indicating a different mechanism of action.
Membrane permeability
In order to observe the permeability effect of peptides on MRSP membrane, we
monitored the fluorescent intensity of bacterial culture mixed with propidium
iodide (PI) after exposure to peptides. As shown in Fig. 3, fluorescence intensity
remained stable during incubation of untreated bacteria in the presence of PI.
This result confirmed the integrity of the bacterial membrane under control
conditions. When exposed to peptides, the cells became permeable to PI and
fluorescence increased within 2 minutes, suggesting very rapid membrane
disruption activity. The permeabilization effect was concentration and time-
dependent. At 5X MIC; nisin, RRIKA, RR and IK8 ‘‘D isoform’’ were faster and
more potent at membrane perturbation in comparison to (KFF)3K, WR-12 and
penetratin (Fig. 3A). However, when the concentration of peptides was increased
to 10 X MIC, similar pattern was observed for all peptides, suggesting dose
dependent activity (Fig. 3B). In contrast, ciprofloxacin, as expected, had no effect
on membrane permeabilization, even at a higher concentration.
Transmission electron microscopy
To explore the possible alternative mechanism of action of peptides on S.
pseudintermedius, transmission electron microscopy (TEM) was done on thin
sections of MRSP (SP3) that had been exposed to peptides for 30 min (Fig. 4).
TEM micrographs of control S. pseudintermedius in dividing cells (Fig. 4A) and
Fig. 2. Growth kinetics of SP3 exposed to 5X MIC of peptides, antibiotics and sterile water (control) as
measured by OD600 by spectrophotometer over time. Results are representative of two separate
experiments, each done in triplicate. Error bars represent standard deviation values.
doi:10.1371/journal.pone.0116259.g002
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single cells (Fig. 4B) displayed round cocci with intact cell membranes and well-
defined cell wall. The nucleoid region showed a non-homogenous electron
density. However, after exposure to peptides, the cytoplasm showed a more
homogenous electron density (Figs. 4C, D and E). At a 1X MIC of RRIKA,
multiple rounded double-layered mesosome-like structures were noticed as well as
rounded bodies in the cytoplasm with similar electron density as that of the septal
cell wall layer (Figs. 4C and D). At 10 X MIC of RRIKA, pore formation and lysed
cells were observed (Fig. 4E&F). RR (at 10 X MIC) showed the most damaging
effect on the cell wall, including alteration in cell wall thickness and cell wall
rupture (Fig. 4G). (KFF)3K caused deviated septa and cytoplasmic inclusions.
(Fig. 4H). Cell wall disintegration and pore formation could be seen in IK8 ‘‘D
Fig. 3. Permeabilization of the cytoplasmic membrane of SP3 as a function of peptide concentration at
5X MIC (A) and 10 X MIC (B), indicated by percent of propidium iodide fluorescence. Each experiment
was done in triplicate, and the values represent means ¡ standard deviations.
doi:10.1371/journal.pone.0116259.g003
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isoform’’ treated bacteria (Fig. 4I). Furthermore, some large non-membrane-
enclosed bodies with similar electron density to that of the cell wall murein layer
were seen in S. pseudintermedius cells at a 10 X MIC of WR-12 (Fig. 4K).
Fig. 4. Transmission electron microscopy (TEM) micrographs of untreated and peptide treated S.
pseudintermedius (SP3). Control bacteria either dividing cells (A) or single celled (B), the cells are round and
intact, with a well-defined cell membrane. The intracellular DNA region exhibits a highly inhomogeneous
electron density. C&D: 1X MIC RRIKA; E&F: 10X MIC RRIKA, G: 10X MIC RR; H: 10X MIC (KFF)3K; I: 10X
MIC IK8 ‘‘D isoform’’; K: 10X MIC WR-12; L: 1X MIC penetratin; M: 10X MIC penetratin.
doi:10.1371/journal.pone.0116259.g004
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Penetratin at 1 X MIC showed the lowest damaging effect (or didn’t show clear
damaging effect) as most cells had normal appearance (data not shown) with the
exception of small percentage of cells that displayed a disintegrated membrane
separated from the cell wall (Fig. 4L). However, at 10 X MIC, large pores were
seen (Fig. 4M). Taken together, these data demonstrate the membrane-damaging
effect of the investigated peptides.
Synergism studies
As shown in Table 4, all peptides displayed synergistic interactions when
combined together. The FIC index varied from 0.37 to 0.5. When peptides were
combined with antibiotics; only (KFF)3K displayed potent synergism with
amikacin and gentamicin with FIC index equal to 0.37 and 0.26, respectively.
However, RRIKA, RR, WR-12, IK-8 and penetratin showed an additive effect with
amikacin and gentamicin. Notably, there were no antagonistic effects observed
between peptides and antibiotics.
Cytotoxicity studies
To evaluate the safety of the peptides toward mammalian cells, we assessed the
cytotoxic effect of different concentration of peptides on macrophage-like cell line
(J774A.1) and human keratinocyte (HaCat) by the MTS assay. IK8 ‘‘D isoform’’
and penetratin peptides did not show any toxicity to mammalian cells at
concentrations up to 256 mM. RR and (KFF)3K peptides were not toxic to
mammalian cells at concentrations up to 64 mM (See Fig. 5). RRIKA and WR-12,
were not toxic up to 32 mM, however they exhibited toxicity at 64 mM (P,0.01)
(See Fig. 5). In contrast, melittin peptide was toxic to J774A.1at 5 mM (P,0.01);
this concentration is equal to the MIC of the melittin.
Table 5 shows IC50 and therapeutic indices of the peptides. All peptides
displayed high therapeutic index, indicating a selective action of these peptides
against S. pseudintermedius.
Table 4. The values of FIC index for the combination of peptides and antimicrobial compounds against Staphylococcus pseudintermedius (SP3).
Compound FIC indexa
RRIKA RR WR-12 IK8 ‘‘D isoform’’ Penetratin (KFF)3K
RRIKA - 0.5 0.5 0.5 0.37 0.37
RR 0.5 - 0.5 0.5 0.5 0.37
WR-12 0.37 0.5 - 0.5 0.5 0.5
IK8 ‘‘D isoform’’ 0.5 0.5 0.5 - 0.75 0.5
Penetratin 0.5 0.37 0.5 0.5 - 0.37
(KFF)3K 0.37 0.37 0.5 0.5 0.37 -
Amikacin 1 0.75 1 0.75 0.75 0.37
Gentamicin 1 0.75 0.75 1 1 0.26
aThe FIC index was determined in the presence of a constant amount of peptide, equal to one -quarter of the peptide MIC.
doi:10.1371/journal.pone.0116259.t004
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Multi-step resistance selection
In order to investigate if the physical perturbation and disruption of microbial
membranes by peptides can adequately overcome conventional mechanisms of
drug resistance, SP6 isolate exposed to sub-inhibitory concentrations of IK8 ‘‘D
isoform’’ and RRIKA were subcultured for ten serial passages to determine if a
shift in the MIC of each peptide tested would be observed against MSSP. Two
classes of clinically used antibiotics including the protein synthesis inhibitor,
amikacin and DNA synthesis inhibitor, ciprofloxacin were included as controls in
this study. As shown in Fig. 6, MSSP was not able to develop resistance to the
peptides despite the repeated exposure with sub-lethal doses of peptides.
However, treatment of SP6 with amikacin induced a shift in the MIC as early as
Fig. 5. Cytotoxicity assay showing the percent mean absorbance at 490 nm after incubating macrophage cell line (J774A.1) (A &B) and human
keratinocyte (HaCat) (C&D) with peptides at different concentrations. Melittin and DMSO served as positive control in J774A.1and HaCat cells,
respectively. Water (peptide diluent) served as negative control. Cell viability was measured by MTS assay. Results are expressed as means from three
measurements ¡ standard deviation. Data were analyzed using one-way ANOVA, with post hoc Tukey’s multiple comparisons test to determine statistical
significance. Two asterisks (**) means statistical different (p,0.01) from the negative control while (ns) means there was no statistical significance from the
negative control.
doi:10.1371/journal.pone.0116259.g005
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passage 4. There was a 32 fold increase in the MIC against amikacin by passage 10.
Ciprofloxacin mediated a slightly delayed onset of drug resistance, with doubling
of MIC occurring later at passage 6 which subsequently increased to 8-fold the
original MIC value by passage 10.
Discussion
The rapid emergence of bacterial resistance among S. pseudintermedius isolates
and the dearth of effective antimicrobials call for alternative strategies to battle
infections caused by this pathogen. One approach which warrants attention as a
potential novel therapy for S. pseudintermedius infections is antimicrobial peptides
(AMPs). There are very few reports describing the antimicrobial activity of
naturally-derived AMPs against S. pseudintermedius [14, 15]. Additionally, there
Table 5. Cytotoxicity and therapeutic index of peptides.
Peptide GM MICa (mM) S. pseudintermedius IC50
b (mM) J774A.1/HaCat TIc J774A.1/HaCat
RRIKA 1.15 64/128 55.6/111.2
RR 4.12 128/256 31/62
WR-12 1.5 128/128 85.3/85.3
IK8 ‘‘D isoform’’ 5 .256/.256 .51.2/.51.2
Penetratin 8.76 .256/.256 .29.2/.29.2
(KFF)3K 7.75 256/.256 33/.33
Melittin 2 2/ND 1/ND
aGM, geometric mean of the MICs of the peptides against S. pseudintermedius strains.
bIC50 (Inhibitory Concentration 50), peptide concentration that inhibits 50% of macrophage cell line (J774A.1) or human keratinocyte (HaCat).
cTI (Therapeutic index), the ratio of the IC50 over the geometric mean MIC value.
ND: not determined.
doi:10.1371/journal.pone.0116259.t005
Fig. 6. Drug resistance development profiles of S. pseudintermedius (SP6) exposed to K X MIC
concentrations of peptides (IK8 ‘‘D isoform’’ and RRIKA) and antibiotics (amikacin and ciprofloxacin)
for 10 serial passages.
doi:10.1371/journal.pone.0116259.g006
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are several drawbacks of naturally-derived AMPs, including high toxicity and
increased cost of production due to the complexity of their design and their large
size, which will limit their translational clinical applications (3, 4). Given the
significant problem posed by the rapid emergence of multidrug-resistant S.
pseudintermedius and the potential benefits of using AMPs as an alternative
therapy, more effort and attention needs to be focused on developing potent,
short, and less toxic AMPs to overcome their therapeutic limitations. In the
present study, six synthetic peptides were investigated for their ability to inhibit
clinical isolates of MSSP and MRSP (see Table 1). These peptides were chosen due
to their short sequence (8–16 amino acids), their simple composition, and their
cationic charge. The AMPs, RR and RRIKA, are derivatives of an anti-
inflammatory cell-penetrating peptide [13, 22, 23]. Previously, the efficacy of these
two peptides against human MRSA clinical isolates were shown in vitro and in a
mouse model of MRSA skin infection [13, 23]. In light of our previous success in
targeting MRSA [13, 23], we tested these two peptides against MSSP and MRSP.
RR exhibited potent antimicrobial activity against clinical isolates of S.
pseudintermedius with MIC50 and MIC90 of 4 mM and 8 mM, respectively.
Furthermore, addition of three amino acids (I, K and A) in the C terminus of RR
significantly enhanced the antimicrobial activity fourfold against S. pseudinter-
medius. This enhancement of activity is probably due to the enhanced
amphipathicity, hydrophobicity, and net charge of the newly derived peptide
RRIKA. RRIKA exhibited antimicrobial activity against clinical isolates of S.
pseudintermedius with MIC50 and MIC90 of 1 mM and 2 mM, respectively.
Additionally, further advantage of using these two peptides has been demon-
strated by their potent activity in physiological concentrations of NaCl and
MgCl2, in contrast to most natural AMPs [13, 24].
Previous studies demonstrated the activity of WR-12 and IK8 ‘‘D isoform’’
peptides against S. aureus [25, 26]. However, their activity against S. pseudinter-
medius was not investigated. WR-12 is a broad-spectrum AMP and consists
exclusively of arginine and tryptophan, arranged to form idealized amphipathic
helices [25]. In our study, WR-12 demonstrated potent antimicrobial activity
against MSSP and MRSP with MIC50 and MIC90 of 1 mM and 2 mM, respectively.
Peptide IK8 ‘‘D isoform’’ in a previous study showed potent antimicrobial
activities against MRSA [26]. Additionally, the D-amino acids substitution of this
peptide prevented proteolytic degradation by mammalian or microbial proteases,
which makes it an excellent candidate for in vivo applications [26]. Peptide IK8
‘‘D isoform’’ in our study exhibited MIC50 and MIC90 of 4 mM and 8 mM,
respectively, against MSSP and MRSP.
The antimicrobial activities of the cell-penetrating peptides (CPPs) have been
widely explored due to their low toxicity and their potential clinical applications
[27–31]. We sought to investigate the antimicrobial activity of two CPPs,
penetratin and (KFF)3K, that share the same characteristic of AMPs, including
basic amino acids composition and cationic charge. The CPPs showed
antimicrobial activity against MSSP with MIC50 and MIC90 of 8 mM and 16 mM,
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respectively. Furthermore, they showed improved activity against MRSP with
MIC50 and MIC90 of 4 mM and 8 mM, respectively.
We assessed the bacterial killing kinetics of the peptides in comparison with the
aminoglycoside antibiotic, amikacin. The peptides showed total and rapid
elimination of S. pseudintermedius within minutes, while amikacin exhibited a
much slower killing kinetic with only 3 log10 reduction after 12 hours incubation
(see Fig. 1). This fast bacterial elimination by the AMPs represents a unique
advantage of the peptides over conventional antibiotics that should lead to better
treatment outcomes.
Understanding the mechanism of antimicrobial activity of these AMPs on S.
pseudintermedius is an essential step for enhancing their activity, reducing their
toxicity, and furthering their development as a potential therapeutic option.
Hence, we explored S. pseudintermedius membrane-perturbing abilities of these
peptides. Growth kinetics study of S. pseudintermedius incubated with the
peptides and control antibiotics revealed a membrane-damaging activity and a
lytic mechanism of action similar to the lytic peptide nisin (see Fig. 2). The
membrane-damaging activity of the peptides was further confirmed by the ability
of propidium iodide (PI) to enter damaged S. pseudintermedius and intercalate
with bacterial DNA. The fluorescence intensity of PI increased significantly after
2 minutes of addition of the peptides, clearly demonstrating their fast
permeabilization characteristic (see Fig. 3). Additionally, transmission electron
microscopy of S. pseudintermedius that had been exposed to the peptides for
30 minutes showed the presence of mesosome structure and damaged membranes
(see Fig. 4). The observed membrane-damaging effect is similar to those seen with
well-characterized AMPs such as defensins and bactenecins [32, 33].
The checkerboard assay was utilized to ascertain whether these peptides have
potential to be combined with each other or with antibiotics against S.
pseudintermedius [34]. Although peptides that work by the same mechanism of
action are less likely to exhibit synergistic activity, our peptides were found to
exhibit a synergistic relationship with each other against S. pseudintermedius (see
Table 4). This finding suggests that, although these peptides share a common
mechanism of action by damaging the bacterial membrane, they may use different
pathways such as barrel-stave, carpet or toroidal-pore to permeabilize the
bacterial membrane [9, 11]. Collectively, these results provide valuable insight into
potential combination therapy that could reduce the dose of each peptide and
minimize potential host toxicity and emergence of resistant pathogens. With the
exception of (KFF)3K, none of the peptides showed synergistic activity with
antibiotics. This result is probably due to their rapid bactericidal activity that
masked the activity of antibiotics [19, 35, 36]. However, (KFF)3K is the only
peptide that displayed potent synergism with the antibiotics, gentamicin and
amikacin. That synergism could be explained by their ability to permeabilize the
membrane, at low concentration, without killing the bacteria, which will enhance
entrance of antibiotics inside bacterial cells.
A significant challenge facing AMPs which has limited their use in therapeutic
applications is associated cytotoxicity to host tissues [37]. However, our peptides
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demonstrated high therapeutic profiles, and there was no toxicity observed on
mammalian cells (J774A.1 and HaCat) at concentrations several times higher than
their bactericidal concentrations (see Table 5 and Fig. 5).
After confirming the potent bactericidal activity of the peptides and their
mechanism of action against S. pseudintermedius, we next turned our attention to
assessing the likelihood that S. pseudintermedius would quickly develop resistance
to these peptides. Repeated subculturing of S. pseudintermedius, in the presence of
sub-inhibitory concentration, in a multi-step resistance selection for ten serial
passages did not result in the development of bacterial resistance to the peptides.
On the other hand, amikacin- and ciprofloxacin-resistant mutants of S.
pseudintermedius readily emerged. The low frequency of emerging bacterial
resistance to AMPs is attributed to the complexity of their mechanism of action
and the extremely difficult changes required by the outer membrane to create a
mutant, which cannot be acquired by simple bacterial mutation [10, 38].
We have successfully demonstrated the potential usage of AMPs against MSSP
and MRSP clinical isolates. The AMPs were superior to antibiotics, demonstrating
potent and rapid bactericidal activity against multidrug resistant S. pseudinter-
medius and low frequency of resistance. Moreover, AMPs such as RR and RRIKA
[23] have been shown to possess potent anti-inflammatory properties and
antibiofilm properties and to enhance wound healing. These are essential qualities
for efficient treatment of skin infections caused by S. pseudintermedius. Taken
together, the characteristics of these AMPs as antimicrobial agents may offer a
significant improvement over current approaches and have a strong potential to
be used for treatment of infections caused by multidrug resistant S.
pseudintermedius.
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